

IFW



Certificate Of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On February 9, 2005
Date

1. Information Disclosure Statement (3 pages, in duplicate);
2. PTO-1449 Form (1 page, in duplicate);
3. Cited References (A1-A2; B1-B4; C1-C4; and
4. This Return Postcard Receipt.


Signature

Karen DiRocco
Typed or printed name of person signing Certificate



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/772,219
Confirmation No.: 2183
Filing Date: February 4, 2004
Examiner:
Group art unit: 1614
Applicants: Green et al.
For: COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES

February 9, 2005
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

(a) Pursuant to Rule 56, it is requested that the documents listed on the accompanying 1449 form be considered and made of record in the above-identified patent application. Copy(ies) of these references B1-B4, and C1-C4 are attached.

- (b) ☒ No fee is believed due because:
- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
 - ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
 - ☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
 - ☒ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
- (c) ☐ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- ☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,



Michael C. Badia, Reg. No. 51,424
Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6467
Fax: (617) 444-6483



Modified Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application Number	10/772,219
Filing Date	February 4, 2004
First Named Inventor	Jeremy Green
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	VPI/02-127 US

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	4,004,009	Jan. 18, 1977	Anderson			
	A2	6,342,601	Jan. 29, 2002	Bantick et al.			

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 02/22601	Vertex Pharmaceuticals, Inc.	21 March 2002	
	B2	WO 03/080616	Glaxo Group Ltd.	2 October 2003	
	B3	WO 2004/072029	Vertex Pharmaceuticals, Inc.	26 August 2004	
	B4	JP 2003-82251	Fuji Photo Film Co. Ltd.	19 March 2003	X

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Patel et al., "Synthesis and Biological Activity of Substituted 1,4,5,6-tetrahydropyridazin-4-ones, 5,6-dihydro-3-hydroxy-1H-pyrazolo [4,3-c]pyridazines and 2,8-dihydro-1H-pyranol[2,3-d]pyridazines", Indian Journal of Chemistry, Vol. 28B, Pages 733-744, September 1989.
	C2	Ghozlan et al., "Synthesis of Polyfunctionally Substituted Pyridazines", Liebigs Ann. Chem., Pages 293-296, 1990.
	C3	Ghozlan et al., "Reactions with 3-oxo-2-phenylhydrazonobutyronitrile: New Routes for the Synthesis of Pyridazines", Gazzetta Chimica Italiana, Vol. 119, Pages 95-97, 1989.
	C4	Witherington et al., "5-Aryl-pyrazolo[3,4-b]pyridazines: Potent Inhibitors of Glycogen Synthase Kinase-3 (GSK-3)", Bioorganic & Medical Chemistry Letters, Vol. 13, Pages 1581-1584, 2003.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Paul Ward/ (11/24/2008)	Date Considered	
--------------------	--------------------------	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.